Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-04. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Types === 2-keto compounds: clorazepate, diazepam, flurazepam, halazepam, prazepam, and others 3-hydroxy compounds: lorazepam, lormetazepam, oxazepam, temazepam 7-nitro compounds: clonazepam, flunitrazepam, nimetazepam, nitrazepam Triazolo compounds: adinazolam, alprazolam, estazolam, triazolam Imidazo compounds: climazolam, loprazolam, midazolam 1,5-benzodiazepines: clobazam
== January 2, 1982 (Saturday) == The Army of Guatemala, in a campaign by President Fernando Lucas Garcia, killed 35 civilians in the village of Pichec, in the Baja Verapaz Department near Rabinal, for their support of the Guerrilla Army of the Poor (Ejército Guerrillero de los Pobres). The killing was the third of the mostly Maya residents of Pichec, in less than nine weeks, with 32 men killed on November 1 and 30 more on November 22. Ahmad Fuad Mohieddin was selected to become the new Prime Minister of Egypt at the request of President Hosni Mubarak, who had held the position of both president and premier since the October 6 assassination of Anwar Sadat. In Denmark, the popular television series Matador broadcast its final episode, watched by 3.5 million viewers in a nation of 5.1 million people. The Clemson University Tigers football team finished in first place in both polls recognized by the NCAA for determining the U.S. major university football championship. In the AP poll of 49 sportswriters, Clemson received 977 points (based on 20 points for a first place vote, 19 for second place, etc.) and the Texas Longhorns 862 points. In the UPI poll of 37 coaches, Clemson had 547 points and the Pitt Panthers 472. In an NFL playoff game nicknamed the "Epic in Miami" as well as "The Game No One Should Have Lost", and ranked in a 2020 survey as the fourth greatest NFL game in the 20th century, the San Diego Chargers defeated the Miami Dolphins, 41 to 38, in overtime, after blowing a 24 to 0 lead in the first quarter.
== Operations == Glenmark operates manufacturing facilities in India, the United States, Argentina, and the Czech Republic. Its oldest plant, in Maharashtra, opened in 1983. Other Indian sites are in Himachal Pradesh, Goa, Madhya Pradesh, and Sikkim. The company also runs a facility in Pilar, Argentina, focused on oncology injectables, and a plant in the Czech Republic acquired through the 2007 purchase of Medicamenta. U.S. corporate offices are in Elmwood Park, New Jersey. The Monroe, North Carolina plant, opened in 2018, is Glenmark's sole U.S. manufacturing site. In August 2021 the company recalled all products made there. The FDA identified 17 manufacturing deficiencies and issued a warning letter in 2022. After corrective actions, a December 2025 inspection was classified as Voluntary Action Indicated, allowing manufacturing to resume. Several Indian facilities have also drawn FDA citations. Good manufacturing practice violations brought a warning letter to the Himachal Pradesh plant in October 2019. The Goa facility was cited in November 2022 for inadequate procedures to verify product strength and purity. A July 2025 warning letter cited the Madhya Pradesh plant for deficiencies in cleaning and testing procedures.
There are many causes of acute liver failure aside from acetaminophen toxicity; these include viral hepatitis—including hepatitis A (rarely), hepatitis B, hepatitis C (rarely), hepatitis E (especially in pregnant women), Epstein–Barr virus, cytomegalovirus and varicella zoster virus -- Wilson's disease, the toxin of the death cap mushroom (Amanita phalloides), alcohol, autoimmune hepatitis, Budd–Chiari syndrome, other medications (including halothane, hormonal contraception, and isoniazid), recreational drugs (including ecstasy [1]) and, rarely, tumours infiltrating the liver. In patients with non-acetaminophen acute liver failure, the following criteria were identified as being associated with a poor prognosis:
Sources: en.wikipedia.org
== Early life and education == Philip E. Dawson obtained his bachelor's degree in chemistry from Washington University in St. Louis, graduating magna cum laude. He went on to earn his Ph.D. in chemistry from Scripps Research in 1996. Following his doctoral studies, Dawson conducted postdoctoral research at the California Institute of Technology before returning to Scripps Research as an assistant professor.
epidemic in the 2000s is related to a number of factors. Rates of opioid use and dependency vary by age, sex, race, and socioeconomic status. With respect to race, the discrepancy in deaths is thought to be due to an interplay between physician prescribing and lack of access to healthcare and certain prescription drugs. Men are at higher risk for opioid use and dependency than women, and men also account for more opioid overdoses than women, although this gap is closing. Women are more likely to be prescribed pain relievers, be given higher doses, use them for longer durations, and become dependent upon them faster. Deaths due to opioid use also tend to skew at older ages than deaths from use of other illicit drugs. This does not reflect opioid use as a whole, which includes younger people. Overdoses from opioids are highest among people between the ages of 40 and 50, in contrast to heroin overdoses, which are highest among people between the ages of 20 and 30. 21- to 35-year-olds represent 77% of people who enter treatment for opioid use disorder, but the average age of first-time use of prescription painkillers was 21.2 years in 2013. Among the middle class, means of acquiring funds include elder financial abuse and international dealers noticing a lack of enforcement in their transaction scams throughout the Caribbean.
The smallpox vaccine is used to prevent smallpox infection caused by the variola virus. It is the first vaccine to have been developed against a contagious disease. In 1796, British physician Edward Jenner demonstrated that an infection with the relatively mild cowpox virus conferred immunity against the deadly smallpox disease. Cowpox served as a natural vaccine until the modern smallpox vaccine emerged in the 20th century. From 1958 to 1977, the World Health Organization (WHO) conducted a global vaccination campaign that eradicated smallpox, making it the only human disease to be eradicated. Although routine smallpox vaccination is no longer performed on the general public, the vaccine is still being produced for research, and to guard against bioterrorism and biological warfare. The term vaccine derives from vacca, the Latin word for cow, reflecting the origins of smallpox vaccination. Edward Jenner referred to cowpox as variolae vaccinae (smallpox of the cow). The origins of the smallpox vaccine became murky over time, especially after Louis Pasteur developed laboratory techniques for creating vaccines in the 19th century. Allan Watt Downie demonstrated in 1939 that the modern smallpox vaccine was serologically distinct from cowpox, and vaccinia was subsequently recognized as a separate viral species. Whole-genome sequencing has revealed that vaccinia is most closely related to horsepox, and the cowpox strains found in Great Britain are the least closely related to vaccinia.
Sources: en.wikipedia.org
Legionnaires' disease is caused by a waterborne bacterium Legionella that grows best in slow-moving or still, warm water. The primary route of exposure is through the creation of an aerosol effect, most commonly from evaporative cooling towers or showerheads. A common source of Legionella in commercial buildings is from poorly placed or maintained evaporative cooling towers, which often release water in an aerosol which may enter nearby ventilation intakes. Outbreaks in medical facilities and nursing homes, where patients are immuno-suppressed and immuno-weak, are the most commonly reported cases of Legionellosis. More than one case has involved outdoor fountains at public attractions. The presence of Legionella in commercial building water supplies is highly underreported, as healthy people require heavy exposure to acquire infection. Legionella testing typically involves collecting water samples and surface swabs from evaporative cooling basins, shower heads, faucets/taps, and other locations where warm water collects. The samples are then cultured and colony forming units (cfu) of Legionella are quantified as cfu/liter. Legionella is a parasite of protozoans such as amoeba, and thus requires conditions suitable for both organisms. The bacterium forms a biofilm which is resistant to chemical and antimicrobial treatments, including chlorine.
== Career in industry == Between the year 1947 and 1969, Beynon was Manager of Physics and Physical, Polymer and Analytical Chemistry at Imperial Chemical Industries. Between 1947 and 1950, Beynon constructed what was to become the first mass spectrometer designed to study organic compounds unrelated to petroleum. He subsequently collaborated with Metropolitan-Vickers to produce the MS8 mass spectrometer, a prototype of the Associated Electrical Industries (AEI) MS9 mass spectrometer. Beynon was made a senior research associate in 1964 which allowed him the opportunity to carry out his own research. He was a Boomer Memorial Fellow at the University of Minnesota in 1965.
April 3 – A United States Air Force F-15E Strike Eagle is shot down over Iran during combat operations. Both crew members are later rescued. During the rescue mission, an A-10 Thunderbolt II is also hit and crashes, though its pilot ejects safely and is recovered. April 4 – 2025–26 NHL season: In ice hockey, the Buffalo Sabres clinched the Stanley Cup playoffs for the first time since the 2010–11 season, ending their 14-year Stanley Cup playoff drought. April 5 Trump posts an expletive-laden message on Truth Social threatening to destroy Iranian power plants and bridges if Iran does not reopen the Strait of Hormuz, writing: "Open the Fuckin' Strait, you crazy bastards, or you'll be living in Hell – JUST WATCH!" The 2026 NCAA Division I women's basketball championship game is held at the Mortgage Matchup Center in Phoenix, Arizona, in which the UCLA Bruins beat the South Carolina Gamecocks 79–51 to win their first title. April 6 The crew of Artemis II breaks the record for the furthest humans have ever been from Earth, reaching a maximum distance of 252,757 miles (406,773 km) as they travel around the far side of the Moon. The Supreme Court vacates a federal appeals court ruling that upheld former Trump advisor Steve Bannon's criminal conviction for contempt of Congress for defying a subpoena from the January 6th Committee. The DOJ moves to formally dismiss Bannon's convictions.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.